BSX · 8-K · 20260729PR000051

Guidance / Outlook

BOSTON SCIENTIFIC CORP · 2026-07-29 · Importance 68 · Surprise 68 · In source text

Boston Scientific now expects full-year 2026 reported sales growth of approximately 5.5% to 6.5% and organic sales growth of 5% to 6%. Full-year adjusted EPS guidance is $3.28 to $3.32. Third-quarter 2026 reported and organic sales growth is expected to be 3% to 5%, with adjusted EPS guidance of $0.80 to $0.82. The second-quarter $0.86 adjusted EPS result exceeded the company’s prior guidance range of $0.82 to $0.84.

Key facts

• The company now estimates full year 2026 net sales growth of approximately 5.5 to 6.5 percent on a reported basis and 5 to 6 percent on an organic basis versus the prior year period. source
• The company now estimates adjusted EPS for full year 2026, excluding certain charges (credits), of $3.28 to $3.32. source
• The company estimates net sales growth for Q3 2026 of approximately 3 to 5 percent on a reported and organic basis versus the prior year period. source
• The company estimates adjusted EPS for Q3 2026, excluding certain charges (credits), of $0.80 to $0.82. source
• Q3 2026 net sales estimate: reported growth low 3.0% and high 5.0%; full year 2026 reported growth estimate low 5.5% and high 6.5%, with operational and organic growth table shown. source

Impact estimates